פלומיסט קואדריוואלנט
astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.
אינפלובאק
abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - תרחיף להזרקה - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.
אינפנריקס אי.פי.וי. איץ'.אי.בי
glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens
אגריפל s1
neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.
אינפלובאק טטרה
abbott medical laboratories ltd, israel - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen
וקסיגריפ טטרא
sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen
פלואריקס טטרה
glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen
אפלואלדה
sanofi israel ltd - a/michigan/45/2015 (h1n1)pdm09 – like strain; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 like strain - תרחיף להזרקה - b/phuket/3073/2013 like strain 60 mcg / 0.7 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 60 mcg / 0.7 ml; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 60 mcg / 0.7 ml; a/michigan/45/2015 (h1n1)pdm09 – like strain 60 mcg / 0.7 ml - influenza, inactivated, split virus or surface antigen
וקסיגריפ
medici medical ltd, israel - a/michigan/45/2015 (h1n1)pdm09-like virus; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) - תרחיף להזרקה - b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) 15 mcg/dose; a/michigan/45/2015 (h1n1)pdm09-like virus 15 mcg/dose; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 15 mcg/dose; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg/dose - influenza, inactivated, whole virus - influenza, inactivated, whole virus - for the prevention of influenza.
הקסקסים
sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; hepatitis b vaccines; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus protein conjugate; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid; tetanus protein conjugate 22 - 36 mcg / 0.5 ml; haemophilus influenzae type b polysaccharide 12 mcg / 0.5 ml; hepatitis b vaccines 10 mcg / 0.5 ml; poliovirus type 3 inactivated 32 du / 0.5 ml; poliovirus type 2 inactivated 8 du / 0.5 ml; poliovirus type 1 inactivated 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus-hepatitis b